Literature DB >> 22430248

Role of type I interferons in the activation of autoreactive B cells.

Kerstin Kiefer1, Michael A Oropallo, Michael P Cancro, Ann Marshak-Rothstein.   

Abstract

Type I interferons (IFNs) are a family of cytokines involved in the defense against viral infections that play a key role in the activation of both the innate and adaptive immune system. IFNs both directly and indirectly enhance the capacity of B lymphocytes to respond to viral challenge and produce cytotoxic and neutralizing antibodies. However, prolonged type I IFN exposure is not always beneficial to the host. If not regulated properly IFN can drive autoantibody production as well as other parameters of systemic autoimmune disease. Type I IFNs impact B-cell function through a variety of mechanisms, including effects on receptor engagement, Toll-like receptor expression, cell migration, antigen presentation, cytokine responsiveness, cytokine production, survival, differentiation and class-switch recombination. Type I IFNs are also cytotoxic for a variety of cell types and thereby contribute to the accumulation of cell debris that serves as a potential source for autoantigens. Type I IFN engagement of a variety of accessory cells further promotes B-cell survival and activation, as exemplified by the capacity of type I IFNs to increase the level of B-cell survival factors, such as B lymphocyte stimulator, produced by dendritic cells. Therefore, it is not surprising that the loss of expression of the type I IFN receptor can have dramatic effects on the production of autoantibodies and on the clinical features of systemic autoimmune diseases such as systemic lupus erythematosus.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22430248      PMCID: PMC3701256          DOI: 10.1038/icb.2012.10

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  106 in total

1.  Interferon treatment of NZB mice: accelerated progression of autoimmune disease.

Authors:  H Heremans; A Billiau; A Colombatti; J Hilgers; P de Somer
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

2.  Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire.

Authors:  J G Cyster; S B Hartley; C C Goodnow
Journal:  Nature       Date:  1994-09-29       Impact factor: 49.962

3.  Serum levels of interferons in patients with systemic lupus erythematosus.

Authors:  T Kim; Y Kanayama; N Negoro; M Okamura; T Takeda; T Inoue
Journal:  Clin Exp Immunol       Date:  1987-12       Impact factor: 4.330

4.  Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors.

Authors:  L E Rönnblom; G V Alm; K E Oberg
Journal:  Ann Intern Med       Date:  1991-08-01       Impact factor: 25.391

5.  The effect of exogenous interferon: acceleration of autoimmune and renal diseases in (NZB/W) F1 mice.

Authors:  C Adam; Y Thoua; P Ronco; P Verroust; M Tovey; L Morel-Maroger
Journal:  Clin Exp Immunol       Date:  1980-05       Impact factor: 4.330

6.  Side effects of high-dose interferon therapy for chronic hepatitis C.

Authors:  T Okanoue; S Sakamoto; Y Itoh; M Minami; K Yasui; M Sakamoto; K Nishioji; T Katagishi; Y Nakagawa; H Tada; Y Sawa; M Mizuno; K Kagawa; K Kashima
Journal:  J Hepatol       Date:  1996-09       Impact factor: 25.083

7.  B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.

Authors:  R John Looney; Jennifer H Anolik; Debbie Campbell; Raymond E Felgar; Faith Young; Lois J Arend; James A Sloand; Joseph Rosenblatt; Iñaki Sanz
Journal:  Arthritis Rheum       Date:  2004-08

8.  Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders.

Authors:  U B Wandl; M Nagel-Hiemke; D May; E Kreuzfelder; O Kloke; M Kranzhoff; S Seeber; N Niederle
Journal:  Clin Immunol Immunopathol       Date:  1992-10

9.  Serum interferon levels in patients with systemic lupus erythematosus.

Authors:  S R Ytterberg; T J Schnitzer
Journal:  Arthritis Rheum       Date:  1982-04

10.  Interferon-alpha induces the expression of the L-selectin homing receptor in human B lymphoid cells.

Authors:  S S Evans; R P Collea; M M Appenheimer; S O Gollnick
Journal:  J Cell Biol       Date:  1993-12       Impact factor: 10.539

View more
  84 in total

Review 1.  Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics.

Authors:  Romain Banchereau; Alma-Martina Cepika; Jacques Banchereau; Virginia Pascual
Journal:  Annu Rev Immunol       Date:  2017-01-30       Impact factor: 28.527

2.  Erythropoietin Treatment Ameliorates Lupus Nephritis of MRL/lpr Mice.

Authors:  Zeming Zhang; Dongmei Liu; Xiaoli Zhang; Xiaofei Wang
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

3.  Differences in codon bias and GC content contribute to the balanced expression of TLR7 and TLR9.

Authors:  Zachary R Newman; Janet M Young; Nicholas T Ingolia; Gregory M Barton
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-22       Impact factor: 11.205

4.  Novel proteasome assembly chaperone mutations in PSMG2/PAC2 cause the autoinflammatory interferonopathy CANDLE/PRAAS4.

Authors:  Adriana A de Jesus; Anja Brehm; Rachel VanTries; Pascal Pillet; Anne-Sophie Parentelli; Gina A Montealegre Sanchez; Zuoming Deng; Isabelle Koné Paut; Raphaela Goldbach-Mansky; Elke Krüger
Journal:  J Allergy Clin Immunol       Date:  2019-01-18       Impact factor: 10.793

Review 5.  Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis.

Authors:  Chandra Mohan; Chaim Putterman
Journal:  Nat Rev Nephrol       Date:  2015-03-31       Impact factor: 28.314

6.  Constitutively Active MDA5 Proteins Are Inhibited by Paramyxovirus V Proteins.

Authors:  Roli Mandhana; Lily K Qian; Curt M Horvath
Journal:  J Interferon Cytokine Res       Date:  2018-08       Impact factor: 2.607

7.  Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification.

Authors:  Melissa E Munroe; Rufei Lu; Yan D Zhao; Dustin A Fife; Julie M Robertson; Joel M Guthridge; Timothy B Niewold; George C Tsokos; Michael P Keith; John B Harley; Judith A James
Journal:  Ann Rheum Dis       Date:  2016-01-25       Impact factor: 19.103

8.  Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity.

Authors:  Yumi Nakayama; Jolanta Kosek; Lori Capone; Eun Mi Hur; Peter H Schafer; Garth E Ringheim
Journal:  J Immunol       Date:  2017-08-28       Impact factor: 5.422

9.  Induction of Systemic Autoimmunity by a Xenobiotic Requires Endosomal TLR Trafficking and Signaling from the Late Endosome and Endolysosome but Not Type I IFN.

Authors:  K Michael Pollard; Gabriela M Escalante; Hua Huang; Katarina M Haraldsson; Per Hultman; Joseph M Christy; Rahul D Pawar; Jessica M Mayeux; Rosana Gonzalez-Quintial; Roberto Baccala; Bruce Beutler; Argyrios N Theofilopoulos; Dwight H Kono
Journal:  J Immunol       Date:  2017-10-20       Impact factor: 5.422

10.  IFN-β treatment requires B cells for efficacy in neuroautoimmunity.

Authors:  Ryan D Schubert; Yang Hu; Gaurav Kumar; Spencer Szeto; Peter Abraham; Johannes Winderl; Joel M Guthridge; Gabriel Pardo; Jeffrey Dunn; Lawrence Steinman; Robert C Axtell
Journal:  J Immunol       Date:  2015-02-02       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.